Artykuł w czasopiśmie
Brak miniatury
Licencja
CC-BYCC-BY - Uznanie autorstwa
 

Cubosomal Lipid Formulation for Combination Cancer Treatment: Delivery of a Chemotherapeutic Agent and Complexed α-Particle Emitter 213Bi

Uproszczony widok
dc.abstract.enHere, we propose tailored lipid liquid-crystalline carriers (cubosomes), which incorporate an anticancer drug (doxorubicin) and complexed short-lived alpha-emitter (bismuth-213), as a strategy to obtain more effective action toward the cancer cells. Cubosomes were formulated with doxorubicin (DOX) and an amphiphilic ligand (DOTAGA-OA), which forms stable complexes with Bi-213 radionuclide. The behavior of DOX incorporated into the carrier together with the chelating agent was investigated, and the drug liberation profile was determined. The experiments revealed that the presence of the DOTAGA-OA ligand affects the activity of DOX when they are incorporated into the same carrier. This unexpected influence was explained based on the results of release studies, which proved the contribution of electrostatics in molecular interactions between the positively charged DOX and negatively charged DOTAGA-OA in acidic and neutral solutions. A significant decrease in the viability of HeLa cancer cells was achieved using sequential cell exposure: first to the radiolabeled cubosomes containing Bi-213 complex and next to DOX-doped cubosomes. Therefore, the sequential procedure for the delivery of both drugs encapsulated in cubosomes is suggested for further biological and in vivo studies.
dc.affiliationUniwersytet Warszawski
dc.contributor.authorCytryniak, Adrianna
dc.contributor.authorBilewicz, Renata
dc.contributor.authorNazaruk, Ewa
dc.contributor.authorBilewicz, Aleksander
dc.contributor.authorMajka, Emilia
dc.contributor.authorWalczak, Rafał
dc.contributor.authorMajkowska-Pilip, Agnieszka
dc.contributor.authorMorgenstern, Alfred
dc.contributor.authorBruchertseifer, Frank
dc.contributor.authorMAMES, Adam
dc.contributor.authorŻelechowska-Matysiak, Kinga
dc.date.accessioned2024-01-24T21:14:27Z
dc.date.available2024-01-24T21:14:27Z
dc.date.copyright2022-07-18
dc.date.issued2022
dc.description.accesstimeAT_PUBLICATION
dc.description.financePublikacja bezkosztowa
dc.description.number8
dc.description.versionFINAL_PUBLISHED
dc.description.volume19
dc.identifier.doi10.1021/ACS.MOLPHARMACEUT.2C00182
dc.identifier.issn1543-8384
dc.identifier.urihttps://repozytorium.uw.edu.pl//handle/item/104008
dc.identifier.weblinkhttps://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.2c00182
dc.languageeng
dc.pbn.affiliationchemical sciences
dc.relation.ispartofMolecular Pharmaceutics
dc.relation.pages2818-2831
dc.rightsCC-BY
dc.sciencecloudnosend
dc.subject.en213Bi radionuclide
dc.subject.encancer cells
dc.subject.encubosomes
dc.subject.encytotoxicity
dc.subject.endoxorubicin
dc.subject.enα-therapy
dc.titleCubosomal Lipid Formulation for Combination Cancer Treatment: Delivery of a Chemotherapeutic Agent and Complexed α-Particle Emitter 213Bi
dc.typeJournalArticle
dspace.entity.typePublication